Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

• Revenue in USD (TTM)40.93m
• Net income in USD-16.25m
• Incorporated2013
• Employees46.00

• Location
  Pieris Pharmaceuticals Inc225 Franklin Street, 26Th FloorBOSTON 02110United StatesUSA
• Phone+1 (857) 246-8998
• Fax+49 (8161) 141-1444
• Websitehttps://www.pieris.com/